Press releases
- Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
- Calliditas Therapeutics to Attend Conferences in April
- Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
- Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
- Calliditas Therapeutics to Attend Investor Conferences in March
- Calliditas Year-end report, January - December 2023
- Invitation to the presentation of Calliditas´ Year-end report January - December 2023
- Calliditas provides patent update
More ▼
Key statistics
On Thursday, Calliditas Therapeutics AB (0A5R:LSE) closed at 100.46, 23.57% above the 52 week low of 81.30 set on Jul 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 100.46 |
Average volume | 4.78k |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 6.01bn SEK |
EPS (TTM) | -8.69 SEK |
Data delayed at least 20 minutes, as of Apr 18 2024 17:57 BST.
More ▼